Learning Outcome: After completing this education activity, the learner will be able to discuss the pharmacologic properties, efficacy and safety of Endothelin Receptor Antagonists.
Contact hours available until 8/31/22.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation.
Authors Conflict of Interest Disclosure: The author(s), editor, editorial committee, content reviewers, and education director reported no actual or potential conflict of interest in relation to this continuing nursing education article.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: This education activity is jointly provided by Anthony J. Jannetti, Inc. (AJJ) and the Academy of Medical-Surgical Nurses (AMSN).
Anthony J Jannetti, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Anthony J. Jannetti, Inc. is an approved provider of continuing nursing education by the California Board of Registered Nurses, Provider Number CEP 5387.
This article was reviewed and formatted for contact hour credit by Michele Boyd, MSN, RN, NPD-BC, AMSN Education Director.
Drugs for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
1.30 - CH
1.00 - Rx
You must be logged in and own this product in order to post comments.
12/3/20 9:42 am
1/12/21 11:39 am
This was a great article, in that we don't get to care for the PAH patients in our MS department. These patients are in our PCUs. Having the opportunity to learn more of the medical management of this disease was vaulable.